Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VIVUS Inc (NASDAQ:VVUS)

1.22
Delayed Data
As of Jun 23
 +0.06 / +5.17%
Today’s Change
0.93
Today|||52-Week Range
1.47
+6.09%
Year-to-Date
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
Jun 23 / Zacks.com - Paid Partner Content
AveXis (AVXS) Surges: Stock Moves 5% Higher
Jun 19 / Zacks.com - Paid Partner Content
Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock
Jun 23 / Zacks.com - Paid Partner Content
Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study
Jun 16 / Zacks.com - Paid Partner Content
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA
Jun 22 / Zacks.com - Paid Partner Content
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
Jun 16 / Zacks.com - Paid Partner Content
Here's Why Geron (GERN) is a Good Stock to Invest in Now
Jun 22 / Zacks.com - Paid Partner Content
Epizyme (EPZM) Jumps: Stock Rises 17.4%
Jun 16 / Zacks.com - Paid Partner Content
Indivor's Opioid Use Disorder Drug Meets Primary Endpoint
Jun 22 / Zacks.com - Paid Partner Content
Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
Jun 16 / Zacks.com - Paid Partner Content
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
Jun 22 / Zacks.com - Paid Partner Content
NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session
Jun 16 / Zacks.com - Paid Partner Content
Novartis Announces Positive Results for Cardiovascular Drug
Jun 22 / Zacks.com - Paid Partner Content
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx
Jun 15 / Zacks.com - Paid Partner Content
BioMarin (BMRN) in Focus: Stock Moves 7% Higher
Jun 22 / Zacks.com - Paid Partner Content
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial
Jun 15 / Zacks.com - Paid Partner Content
Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%
Jun 22 / Zacks.com - Paid Partner Content
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
Jun 14 / Zacks.com - Paid Partner Content
Novartis Migraine Drug Accepted, AMD Positive in Phase III
Jun 21 / Zacks.com - Paid Partner Content
Omeros (OMER) Lead Candidate Gets Breakthrough Designation
Jun 14 / Zacks.com - Paid Partner Content
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
Jun 21 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
Jun 14 / Zacks.com - Paid Partner Content
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
Jun 21 / Zacks.com - Paid Partner Content
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial
Jun 13 / Zacks.com - Paid Partner Content
Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session
Jun 21 / Zacks.com - Paid Partner Content
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
Jun 13 / Zacks.com - Paid Partner Content
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
Jun 20 / Zacks.com - Paid Partner Content
Intercept (ICPT) Releases Data from Phase II Flint Trial
Jun 13 / Zacks.com - Paid Partner Content
Horizon Pharma Gets Health Canada Approval for Procysbi
Jun 20 / Zacks.com - Paid Partner Content
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
Jun 13 / Zacks.com - Paid Partner Content
Rigel Pharmaceuticals' NDA for Tavalisse Accepted by FDA
Jun 20 / Zacks.com - Paid Partner Content
GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up
Jun 13 / Zacks.com - Paid Partner Content
Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA
Jun 20 / Zacks.com - Paid Partner Content
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
Jun 13 / Zacks.com - Paid Partner Content
Merrimack Completes Enrollment in Phase II Study for MM-141
Jun 20 / Zacks.com - Paid Partner Content
Lilly Plans New Outcomes Study to Expand Jardiance Label
Jun 13 / Zacks.com - Paid Partner Content
Seattle Genetics Halts Phase III Study on Leukemia Drug
Jun 20 / Zacks.com - Paid Partner Content
Novartis Presents Positive Data on CAR-T Cell Therapy Drug
Jun 12 / Zacks.com - Paid Partner Content
Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%
Jun 20 / Zacks.com - Paid Partner Content
Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M
Jun 12 / Zacks.com - Paid Partner Content
Celgene Presents Interim Results from Cancer Drug Study
Jun 19 / Zacks.com - Paid Partner Content
J&J Announces EU Regulatory Approval for Actelion Deal
Jun 12 / Zacks.com - Paid Partner Content
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
Jun 19 / Zacks.com - Paid Partner Content
Alkermes Commences Phase III Study for Schizophrenia Drug
Jun 12 / Zacks.com - Paid Partner Content
GlaxoSmithKline's Benlysta Positive in Continuation Trial
Jun 19 / Zacks.com - Paid Partner Content